Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine最新文献

{"title":"Infectious risks of transfusion: A 10-year look back and perspectives.","authors":"Evan M Bloch, Steven J Drews, Jeremy W Jacobs","doi":"10.1016/j.tracli.2026.09.004","DOIUrl":"10.1016/j.tracli.2026.09.004","url":null,"abstract":"<p><p>Almost 50 years following the advent -and ensuing tragedy- of transfusion-transmitted HIV, infectious diseases continue to shape blood transfusion practice and policy. Over the past decade alone, a myriad of changes span innovation in donor selection, testing and pathogen reduction, to emergence and re-emergence pathogens that have required evaluation and, in some cases, active intervention. Major developments include refined bacterial testing, novel findings on cold storage of platelets along with the expanded use of pathogen reduction to address the risk of bacterial contamination. Notable pathogens include Zika virus, Plasmodium (malaria), Babesia (babesiosis) and SARS-CoV-2 (COVID-19), the latter spurring a historic pandemic. SARS-CoV-2 highlighted the potential for emerging infectious diseases to impact the blood supply, independent of whether transfusion transmissible. The pandemic afforded new insight into convalescent plasma and how passive immunotherapy can be used to treat infectious diseases. Other favorable developments include a transition to individualized risk assessment and the relaxation of longstanding donor deferral policies (e.g. variant Creutzfeldt-Jacob disease), which have helped to alleviate the transfusion deficit. Progress in artificial intelligence and machine learning has yielded novel tools for surveillance and horizon scanning that enable early recognition of threats and opportunities for transfusion services to contend with infectious diseases. Nonetheless, many of the favorable developments do not extend to low and low-middle income countries, where replacement donation, suboptimal laboratory-based screening with limited molecular testing, and near-absent post-transfusion surveillance, continue to contribute to transfusion-transmitted infection. We reflect on the impact of infectious diseases on transfusion services over the last ten years (2016-2026).</p>","PeriodicalId":94255,"journal":{"name":"Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148984578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Engraftment kinetics and early clinical outcomes following hematopoietic stem cell transplantation: A prospective observational study from a tertiary care hospital in Uttarakhand.","authors":"Tushar Bhardwaj, Manish Raturi, Avriti Baveja","doi":"10.1016/j.tracli.2026.08.004","DOIUrl":"10.1016/j.tracli.2026.08.004","url":null,"abstract":"<p><strong>Background: </strong>Hematopoietic stem cell transplantation (HSCT) is an established treatment for several malignant and non-malignant hematological disorders. The timing and success of hematopoietic engraftment are important early indicators of transplant recovery.</p><p><strong>Objective: </strong>To describe neutrophil and platelet engraftment kinetics after HSCT and to explore associations of engraftment with patient characteristics, transplant compatibility, graft characteristics, transfusion requirements, and early recorded survival status.</p><p><strong>Methods: </strong>This prospective observational study included 45 consecutive patients undergoing autologous or allogeneic HSCT at a tertiary-care transplant centre in Dehradun, India. Engraftment was defined using predefined neutrophil and platelet count criteria. Patient, transplant, compatibility, graft-quality, transfusion, and early follow-up variables were extracted from the master clinical dataset. Continuous variables were compared using the two-sided Mann-Whitney U test and categorical variables using Fisher's exact test.</p><p><strong>Results: </strong>Successful hematopoietic engraftment occurred in 40/45 patients (88.9%). Mean neutrophil and platelet engraftment occurred at 13.47±2.99 days and 15.53±4.73 days, respectively. Pre-transplant peripheral-blood CD34+ count was lower in the engraftment group but was not statistically significant (37.15±37.41 vs. 83.59±68.11; P=0.148). Final infused CD34+ cell dose was also not significantly different (9.15±4.95 vs. 8.60±5.66×10⁶/kg; P=0.732). ABO compatibility was not significantly associated with engraftment (32/35 vs. 8/10; P=0.306; OR: 2.67, 95% CI: 0.38-18.74). Product viability was lower in the engraftment group (96.34±2.94% vs. 98.69±0.92%; P=0.045), although this finding should be interpreted cautiously given the small number of non-engraftment events and multiple comparisons. Three deaths occurred, all among patients with non-engraftment.</p><p><strong>Conclusion: </strong>In this heterogeneous single-centre cohort, most patients achieved hematopoietic engraftment within the first three weeks after HSCT. Neither pre-transplant circulating CD34+ count, final infused CD34+ dose, nor ABO compatibility showed a statistically significant association with engraftment. The small sample size and only five non-engraftment events limit causal inference and multivariable analysis. Larger prospective cohorts with longitudinal donor-chimerism and time-to-event data are required.</p>","PeriodicalId":94255,"journal":{"name":"Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148815314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AINAR trial: A randomized controlled trial to assess the usefulness of artificial intelligence-based game to conquer needle fear in blood donors.","authors":"Radheshyam Meher, Gopal K Patidar","doi":"10.1016/j.tracli.2026.09.001","DOIUrl":"10.1016/j.tracli.2026.09.001","url":null,"abstract":"<p><strong>Background: </strong>Needle fear and anxiety are important contributors to vasovagal reactions (VVR) and poor retention among blood donors. This study evaluated the usefulness of Artificial Intelligence for Needle Anxiety Reduction (AINAR), an artificial intelligence-based game intervention, in reducing needle fear and VVR during blood donation.</p><p><strong>Methodology: </strong>Single-centre, parallel-group randomized controlled trial conducted at AIIMS, New Delhi (2025). Total of 3000 eligible whole blood donors were randomized equally into control and AINAR groups. Donors in the intervention arm played the AINAR game during needle insertion and removal. The primary outcome was immediate VVR incidence. Secondary outcomes included needle fear, anxiety scores, and AINAR colour feedback responses. Fear and anxiety were assessed using a 5-point Likert scale before and after donation.</p><p><strong>Results: </strong>The overall incidence of VVR was 1.47%. VVR occurred in 1.8% of donors in the control group and 1.13% in the AINAR group, corresponding to a relative risk of 0.63, representing a reduction that did not reach statistically significance. Needle fear significantly decreased after donation in both groups, with a greater reduction in the AINAR group. Moderate-to-severe pre-donation needle fear was strongly associated with VVR (5.6 vs. 1.3%, P<0.001). Persistent post-donation fear was strongly associated with VVR (aOR 9.19, 95% CI 3.19-26.48), while prior VVR also remained independently associated with VVR (aOR 4.65, 95% CI 1.15-18.82). Exploratory subgroup analyses suggested lower VVR incidence with AINAR among some higher-risk donor groups. AINAR colour changes correlated with donor-reported fear and anxiety.</p><p><strong>Conclusion: </strong>AINAR was associated with a greater reduction in donor-reported needle fear, whereas the reduction in immediate VVR did not reach statistical significance. Exploratory findings among high-risk donors warrant further investigation. Larger multicentre studies are required to determine whether AI-assisted behavioural interventions can reduce VVR and improve donation experience.</p>","PeriodicalId":94255,"journal":{"name":"Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148908522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Platelet transfusion response and engraftment after hematopoietic stem cell transplantation: An underexplored interface.","authors":"Naveen Bansal, Mohammed Umar","doi":"10.1016/j.tracli.2026.08.005","DOIUrl":"10.1016/j.tracli.2026.08.005","url":null,"abstract":"","PeriodicalId":94255,"journal":{"name":"Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148857926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to \"Transfusion rate and risk factors in hemiarthroplasty of hip: A nationwide cohort study\" [Transfus. Clin. Biol. 2026;33(3):179-186].","authors":"Ki-Tae Park, Jung-Wee Park, Dong-Hoon Lee, Soon Young Park, Min-Ji Han, Young-Kyun Lee","doi":"10.1016/j.tracli.2026.07.009","DOIUrl":"https://doi.org/10.1016/j.tracli.2026.07.009","url":null,"abstract":"","PeriodicalId":94255,"journal":{"name":"Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148820738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Recommendations for immunohematological management of pregnancy. Working group: Fetal-maternal anti-red blood cells alloimmunization from the French-speaking Blood Transfusion Society].","authors":"Cécile Toly-Ndour, Elodie Piccione, Charlotte Magdelaine, Aline Floch, Isabelle Vinatier, Jean-Marc Minon, Gauthier Alluin, Emmanuelle Guinchard, Laurence Delugin, Christine Kimmel, Vanessa Ratié, Marie-Luce Boennec, Hélène Petit, Nadia Oubouzar, Laurine Laget, Muriel Bouton, Djamel Bakour, Bénédicte Debiol, Said Amrouche, Anne Cortey, Agnès Mailloux","doi":"10.1016/j.tracli.2026.08.003","DOIUrl":"10.1016/j.tracli.2026.08.003","url":null,"abstract":"<p><p>Immunohematological (IH) monitoring during pregnancy is of critical importance for both fetal and maternal outcomes. For the fetus, it enables the Rh disease prevention, the diagnosis and the follow-up of fetal-maternal erythrocytes incompatibilities (FMEI), while for the mother, it allows anticipation of potential transfusion requirements. The diagnosis of FMEI relies on rigorously conducted IH surveillance, in compliance with the recommended schedule for anti-red blood cells antibody screening as defined by the French National Authority for Health (HAS), as well as with current regulatory frameworks (2018 regulatory order). In 2018, a working group was established within the French Society of Blood Transfusion (SFTS) with the objective of evaluating current practices in IH monitoring of pregnancies in France and subsequently developing more detailed recommendations to optimize patient management. Based on two national surveys-a questionnaire assessing laboratory practices and a registry of cases involving suboptimal management associated with inadequate IH monitoring-as well as a systematic review of the literature conducted according to the GRADE methodology, the working group formulated recommendations for IH monitoring in pregnant women that cover all the medical biology examinations process. Particular emphasis was placed on the following aspects: - The anti-red blood cells antibody screening schedule, including the recommendation to perform screening at six months of gestation, irrespective of the patient's D (RH1) status. - The utility of screening panels designed to detect the widest possible range of clinically significant alloantibodies associated with obstetric risk, ideally including C^w+ and Kp^a+ red blood cells. - The indications for implementing quantification techniques beyond standard titration, notably anti-D microtitration and quantitative assays. - The importance of providing expert interpretative comments alongside laboratory results; in cases of fetal-maternal incompatibility. This includes specifying the risk of hemolytic disease of the fetus and newborn (HDFN) based on the specificity and concentration of maternal antibodies, as well as recommending appropriate monitoring intervals. - The procedures for timely and effective communication of results-particularly abnormal findings-to the sampling laboratory, clinicians, and/or transfusion services.</p>","PeriodicalId":94255,"journal":{"name":"Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148820752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical utility of LLM-assisted chart review for the detection of bleeding events.","authors":"Merijn C Reuland, Oscar M van der Meer, Alberto Testoni, Pieter O L P Broeren, Dave A Dongelmans, Paul W G Elbers, Marcella C A Müller, Senta Jorinde Raasveld, Alexander P J Vlaar","doi":"10.1016/j.tracli.2026.07.005","DOIUrl":"10.1016/j.tracli.2026.07.005","url":null,"abstract":"<p><strong>Introduction: </strong>Red blood cell (RBC) transfusions are frequently administered in the intensive care unit (ICU) and are independently associated with increased mortality. While most studies have focused on transfusion events, bleeding events that do not result in transfusion remain understudied. The validated HEME scoring system enables structured bleeding assessment but requires labor-intensive chart review, limiting scalability. We hypothesized that large language models (LLMs) could function as screening instruments to facilitate scalable chart review and support the development of curated bleeding event datasets.</p><p><strong>Methods: </strong>This retrospective cohort study included critically ill patients at high risk of bleeding. Reference data on in-ICU bleeding events were derived from prior manual review using the Hemorrhage Measurement (HEME) scoring system. For the LLM-based analysis, unstructured clinical notes were extracted from the electronic health record (EHR) for the same patient cohort. Notes were processed via structured JSON-formatted prompts using the OpenAI gpt-4o-mini model in a secure environment. Next, these bleeding events were adjudicated to come to a verified reference set.</p><p><strong>Results: </strong>In 149 patients 36 490 notes were analyzed. A total of 654 adjudicated true bleeding events were identified in the reference set. Manual review detected 66 events, while the LLM detected 647 events. Manual review identified 7 true events missed by the LLM 1.1% (7/654). The LLM identified 588 true events not captured by manual review, corresponding to an incremental detection yield of 90.1% (588/654). Among the 739 events identified by the LLM, 85 were not confirmed upon adjudication, resulting in a false-positive rate of 11.5% (85/739). The LLM correctly classified bleeding site in 42% of cases (272/654) and bleeding severity in 65% of cases (424/654).</p><p><strong>Conclusion: </strong>Use of an LLM substantially increased detection of ICU bleeding events compared with manual review. However, an 11.5% false-positive rate and limited accuracy in site and severity classification indicate that expert adjudication remains necessary.</p>","PeriodicalId":94255,"journal":{"name":"Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148763338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrected count increment after living donor liver transplantation: Predictor or marker of evolving graft dysfunction?","authors":"Yaqin Huang, Zhuo Chen","doi":"10.1016/j.tracli.2026.08.002","DOIUrl":"10.1016/j.tracli.2026.08.002","url":null,"abstract":"","PeriodicalId":94255,"journal":{"name":"Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148765455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of an integrated Anatomy-Transfusion Medicine program on knowledge acquisition among first-year MBBS students and Laboratory technicians: A quasi-experimental pre-post educational intervention study.","authors":"Juilee Shalik Charmode, Manish Raturi, Kirubhanand Chandrasekaran, Parag Prabhakar Fulzele, Aaditya M Tarnekar, Neema Vijay, Soumya Das, Rounak Dubey","doi":"10.1016/j.tracli.2026.08.001","DOIUrl":"10.1016/j.tracli.2026.08.001","url":null,"abstract":"<p><strong>Background: </strong>Competency-based medical education emphasizes early clinical exposure and integration of basic and clinical sciences. We evaluated the effectiveness of an integrated anatomy and transfusion medicine workshop in improving knowledge among first-year MBBS students and laboratory technicians.</p><p><strong>Methods: </strong>A quasi-experimental pre-post educational intervention study was conducted among first-year MBBS students and laboratory technicians attending a workshop on cubital fossa anatomy, venipuncture, bone marrow anatomy and related transfusion medicine procedures. Knowledge was assessed using an identical 11-item multiple-choice questionnaire administered immediately before and after the workshop. The primary analysis included MBBS students. Laboratory technicians attending the same workshop were analyzed separately as a descriptive subgroup. Paired t-test, Wilcoxon signed-rank test, 95% confidence intervals and Cohen's d_z were used for analysis.</p><p><strong>Results: </strong>Thirty-three first-year MBBS students were included in the primary analysis. Mean pre-workshop score increased from 8.09 ± 1.40 to 10.06 ± 1.09 after the workshop, with a mean paired improvement of 1.97 marks (95% CI: 1.50 to 2.44; paired t-test P<0.001; Wilcoxon P<0.001). The effect size was large (Cohen's d_z=1.48). Thirty students (90.9%) improved and three (9.1%) remained unchanged; no student showed a decline. The proportion scoring at least 70% increased from 60.6% to 97.0%. Among six technicians, mean score improved from 5.17 ± 1.17 to 8.50 ± 0.84.</p><p><strong>Conclusion: </strong>An integrated Anatomy-Transfusion Medicine workshop produced significant significantly improved students' immediate knowledge. Such multidisciplinary, clinically focused teaching sessions can effectively supplement routine anatomy education in competency-based medical curricula.</p>","PeriodicalId":94255,"journal":{"name":"Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148698595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transfusion support after CAR-T cell therapy: Real-world patterns across commercial products and disease groups.","authors":"Jay Patel, Denise L Pereira, Damian Green, Amer Beitinjaneh, Noa G Holtzman, Mark S Goodman, Antonio M Jimenez Jimenez, Lazaros Lekakis, Jay Spiegel, Trent Wang, Claudette Gail Edwards, Cara Benjamin, Yanyun Wu, Abdulaziz F Al Mana","doi":"10.1016/j.tracli.2026.07.008","DOIUrl":"10.1016/j.tracli.2026.07.008","url":null,"abstract":"<p><strong>Background: </strong>Chimeric antigen receptor (CAR) T-cell therapy is frequently complicated by prolonged cytopenias requiring transfusion. Comparative real-world data on transfusion burden across commercial CAR-T products and post-therapy alloimmunization risk remain limited.</p><p><strong>Methods: </strong>We retrospectively reviewed 102 patients treated with idecabtagene vicleucel (Abecma), ciltacabtagene autoleucel (Carvykti), lisocabtagene maraleucel (Breyanzi), axicabtagene ciloleucel (Yescarta), or brexucabtagene autoleucel (Tecartus) at a single center. Red blood cell (RBC) and platelet transfusions were quantified over 0-30, 30-90, and 90-180days post-infusion. Kruskal-Wallis tests and negative binomial regression with disease-stratified interpretation were used to estimate incidence rate ratios with 95% confidence intervals. Alloimmunization was assessed through routine, clinically driven antibody screening.</p><p><strong>Results: </strong>Adjusted exploratory models detected no product-specific differences in RBC support. Platelet transfusion distributions varied by product and disease group, but these findings were based on small absolute counts and were driven by a minority of high-need patients; therefore, they should be interpreted as hypothesis-generating rather than definitive product-level differences. No new RBC alloantibodies were detected through routine clinical antibody screening.</p><p><strong>Conclusion: </strong>Transfusion needs after CAR-T therapy were concentrated in the first 30days and were modest overall, with most patients transfusion-free thereafter. This real-world descriptive analysis helps fill a current gap in understanding transfusion-support patterns across commercial CAR-T products and disease groups. Apparent product- and disease-related differences were driven by a minority of high-need patients and should be considered hypothesis-generating. No new RBC alloantibodies were detected through routine clinical screening, although standardized antibody surveillance was not performed.</p>","PeriodicalId":94255,"journal":{"name":"Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148498619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}